About
Health Care

Health Care

Tracking Health Care legal and regulatory developments.

9 entries in Tech Counsel Tracker

LawSnap Briefing Updated October 8, 2026

State of play.

Where things stand.

  • FTC enforcement against DTC health platforms is now in active litigation. The Hims & Hers complaint — following a nearly three-year investigation — targets pixel-based health data sharing with ad platforms and pre-consultation billing as overlapping violations of the FTC Act, ROSCA, and state consumer protection statutes; the case will produce discovery on how tracking technologies transmit health information to third parties (→ FTC, Utah, and California Sue Hims & Hers Over Health Data and Billing Practices, FTC, California, and Utah Sue Hims & Hers Over Health Data and Billing Practices, FTC, Utah, and California Sue Hims & Hers Over Health Data Sharing).
  • Federal Medicaid data-sharing with DHS is under injunction litigation. A 16-state coalition challenges HHS's grant of unrestricted ICE access to Medicaid beneficiary health information; the outcome will determine whether states can impose use-limitation conditions on federally administered health data (→ Washington se suma a demanda contra HHS por compartir datos médicos con DHS).
  • State AI therapy restrictions are enacted law, not pending regulation. Seven states — Colorado, Maine, Rhode Island, Tennessee, Vermont, Illinois, and Nevada — have enacted restrictions ranging from outright prohibition to licensing and disclosure requirements; no federal standard governs the space, and dozens of additional state bills remain active (→ States tighten rules on AI therapy chatbots amid rising mental health use).
  • AI whistleblower litigation in healthcare has reached federal court. The Mayo Clinic suit under the False Claims Act's retaliation provision alleges suppression of a 67% error rate in the MAYA tool and IRB bypass — the first major case to test FCA retaliation as a vehicle for AI safety concerns in a clinical deployment (→ Former Mayo Clinic AI Director Sues System Over Alleged Retaliation and AI Safety Cover-Up).
  • State AGs are pursuing pandemic-era accountability through state-law self-dealing theories. Florida, West Virginia, and Louisiana have issued investigative subpoenas to Dr. Fauci; a federal pardon does not shield against state investigations, making the jurisdictional scope of these probes a live question for practitioners tracking pandemic-era liability (→ Florida AG subpoenas Anthony Fauci in multi-state probe over COVID-era self-dealing).
  • ACA marketplace design is in active litigation. A 21-state coalition challenges the Trump administration's 2027 Notice of Benefit and Payment Parameters, alleging it unlawfully expands catastrophic plan eligibility and resurrects provisions a federal court previously vacated; HHS's own estimates project 2 million coverage losses in 2027 rising to 5 million by 2030 (→ California AG Bonta Sues to Block Trump Rule Expanding Catastrophic ACA Plans).
  • Healthcare governance disputes are producing competing civil extortion and financial misconduct claims. The American Healthcare Systems litigation — involving a five-hospital Florida network, $14 million in disputed funds, and an amended complaint that reverses the original plaintiff-defendant alignment — illustrates control-failure risk in founder-led health systems (→ American Healthcare Systems Files Amended Complaint Against Former Counsel Over Takeover Scheme).
  • International AI safety frameworks are hardening around healthcare as a high-risk sector. The UN International AI Safety Report 2026, drawing on World Bank and World Economic Forum research, identifies healthcare AI as an area where capability is outpacing governance; the WEF ranked adverse AI outcomes as the fifth most critical global risk (→ UN releases 2026 International AI Safety Report warning of enormous benefits and existential risks).
  • AI scribe consent litigation remains a pattern. Class actions against Sutter Health and MemorialCare follow the Sharp HealthCare template, placing institutional liability — not vendor liability — on health systems for ambient recording without patient consent under CIPA, CMIA, and the Federal Wiretap Act .
  • Genetic data de-identification is contested doctrine. Tempus AI's defense that transferred Ambry Genetics data was de-identified faces the argument that genetic information is inherently identifiable — unresolved under state genetic privacy statutes .

Latest developments.

Active questions and open splits.

  • Whether pixel-based health data transmission to ad platforms constitutes an FTC Act violation independent of HIPAA coverage. The Hims & Hers complaint proceeds under FTC Act and ROSCA — not HIPAA — meaning the case will test whether FTC consumer protection authority reaches health data sharing that falls outside HIPAA's covered entity framework (→ FTC, Utah, and California Sue Hims & Hers Over Health Data and Billing Practices, FTC, California, and Utah Sue Hims & Hers Over Health Data and Billing Practices, FTC, Utah, and California Sue Hims & Hers Over Health Data Sharing).
  • Whether states can impose use-limitation conditions on federally administered Medicaid data. The HHS-DHS data-sharing litigation presents a structural question about state authority over federal program data — no circuit has resolved it; a preliminary injunction ruling will be the first significant signal (→ Washington se suma a demanda contra HHS por compartir datos médicos con DHS).
  • Whether the FCA retaliation provision extends to AI safety concerns in clinical AI deployments. The Mayo Clinic suit is the first major test; if courts sustain the FCA theory, every health system deploying clinical AI tools faces a new whistleblower exposure vector tied to validation documentation and error-rate disclosure (→ Former Mayo Clinic AI Director Sues System Over Alleged Retaliation and AI Safety Cover-Up).
  • What compliance framework satisfies the seven-state AI therapy patchwork for multi-jurisdiction mental health platforms. State approaches range from outright prohibition (Colorado) to licensing and disclosure requirements — with no federal floor and dozens of additional bills pending; a platform compliant in one state may be unlawful in another (→ States tighten rules on AI therapy chatbots amid rising mental health use).
  • Whether HHS can reintroduce ACA provisions previously vacated by federal courts through new rulemaking. The 21-state coalition's challenge to the 2027 marketplace rule turns on this question; if sustained, it constrains executive authority over ACA marketplace design going forward (→ California AG Bonta Sues to Block Trump Rule Expanding Catastrophic ACA Plans).
  • Whether health systems or vendors bear primary liability for AI scribe consent failures. The Sutter/MemorialCare complaints name only health systems — not Abridge — but vendor agreements, BAA structures, and indemnification provisions will determine ultimate allocation; courts have not yet resolved the institutional-vs.-vendor split .
  • Whether genetic data can be meaningfully de-identified under state genetic privacy statutes. Tempus AI's de-identification defense remains untested at the class action level; the outcome governs post-acquisition data integration and downstream licensing structures across life sciences M&A .

What to watch.

9 Contributing Entries

OpenAI Says ChatGPT Will Get Better Follow-Up Questions and Crisis Detection With Clinician Input

OpenAI is reportedly retuning ChatGPT's prompting and response-checking so the model asks more useful follow-up questions and can tell routine queries apart from emerging mental-health crises. The company says the changes draw on clinical guidance from mental-health professionals and are meant to reduce delusion-reinforcing and misleading replies, with more appropriate escalation to professional help. The claimed gains, including a drop in fabricated outputs, come from early testing that has not been independently verified.

October 10, 2026
Details arrow_forward

Pfizer CEO Bourla Hands AI Decisions to Business Unit Heads After Slow Two-Year Rollout

Pfizer is restructuring how it runs artificial intelligence, shifting decisions from a central team of specialists to the business leaders closest to each domain. CEO Albert Bourla told the Wall Street Journal's CEO Brief that the change reverses his earlier approach, which he said had stalled. He described progress under the old model as "stagnation," despite two years of enterprise-wide AI integration. Under the new setup, domain leaders make the AI calls and are accountable for how workflows and operations change, while a central team provides support. Bourla says the move reduced internal resistance and sped adoption, and reporting describes cross-functional groups called "clans" that link departments. The story was reported October 9, 2026.

October 9, 2026
Details arrow_forward

FDA Clears Happy Health Smart Ring for Cuffless Blood Pressure Monitoring (Oct 8, 2026)

The FDA has cleared Happy Health's smart ring for continuous, cuffless, calibrationless blood pressure monitoring, adding to the company's existing FDA clearance for at-home sleep apnea diagnosis. The clearance rests on a validation study of 850 paired measurements from 85 patients, compared against arterial-line readings and covering a range from normal pressure through stage 2 hypertension. It landed three days before this report and is one of several recent clearances for consumer blood pressure technology. Apple's FDA-cleared hypertension feature, which analyzes 30 days of optical pulse data and issues a notification without showing a number, and Aktiia's Hilo band, cleared in July 2025 for calibrated readings using an upper-arm cuff, are among the others.

October 11, 2026
Details arrow_forward

California expands PFAS fraud case against DuPont spinoffs over asset transfers

California Attorney General Rob Bonta filed a Second Amended Complaint in the state's PFAS litigation, alleging that DuPont-related companies executed fraudulent asset transfers designed to shield themselves from environmental liability. The complaint targets E. I. du Pont de Nemours and Company, DuPont de Nemours, Inc., Corteva, Inc., The Chemours Company, and newly created Qnity Electronics. Bonta contends that corporate restructuring and amended agreements shifted the bulk of PFAS-related liabilities onto Chemours while reducing exposure for New DuPont, Corteva, and Qnity Electronics. The filing invokes the Uniform Fraudulent Transfer Act and the Uniform Voidable Transactions Act, and seeks relief in U.S. District Court for the District of South Carolina.

UN releases 2026 International AI Safety Report warning of enormous benefits and existential risks

The United Nations released the International AI Safety Report 2026, a comprehensive assessment concluding that advanced artificial intelligence presents both transformative opportunities and escalating dangers. The report, led by the UN agency for digital technology, finds that AI can accelerate development in health, education, and financial services in developing nations while simultaneously enabling cyberattacks, deepfake fraud, non-consensual intimate imagery, and biological weapon design. The core finding: AI capabilities in critical fields like biological research are advancing faster than governance frameworks, creating a dangerous gap between what is technologically possible and what remains safe.

FTC, Utah, and California Sue Hims & Hers Over Health Data and Billing Practices

The FTC, joined by Utah and California, sued telehealth company Hims & Hers Health, Inc. on July 29, 2026, in U.S. District Court for the Northern District of California. The complaint alleges that Hims shared consumers' sensitive health information with third-party ad platforms including Meta and Snap despite privacy commitments, and that it charged customers for prescriptions immediately after intake forms were completed—before any provider consultation occurred. The agencies also claim Hims misled customers about billing, subscriptions, and cancellation procedures. The FTC alleges violations of the FTC Act and the Restore Online Shoppers' Confidence Act (ROSCA), while Utah and California assert violations of state consumer protection and false-advertising statutes.

FTC, California, and Utah Sue Hims & Hers Over Health Data and Billing Practices

The Federal Trade Commission, joined by California and Utah, has sued telehealth company Hims & Hers Health, Inc. in U.S. District Court for the Northern District of California, alleging that the company shared sensitive health data with advertising platforms including Meta and Snap while marketing itself as private and discreet. The complaint also charges Hims with deceptive subscription practices, including charging customers immediately after intake forms were submitted—before any medical consultation occurred—and making cancellation unreasonably difficult. The FTC alleges violations of the FTC Act and the Restore Online Shoppers' Confidence Act, while California invokes its False Advertising and Unfair Competition Laws and Utah cites its Consumer Sales Practices Act.

FTC, Utah, and California Sue Hims & Hers Over Health Data Sharing

The FTC, joined by Utah and California, filed a federal complaint in the U.S. District Court for the Northern District of California against Hims & Hers Health, Inc., alleging the telehealth company shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap while publicly promising privacy protection. The complaint also charges that Hims & Hers misled users about billing and cancellation practices. According to the filing, the company disclosed health-related data and customer lists through tracking technologies embedded on its website, charged consumers for prescriptions immediately after intake forms were submitted—before any provider consultation occurred—and deliberately made subscriptions difficult to cancel. The FTC alleges violations of the FTC Act and the Restore Online Shoppers' Confidence Act (ROSCA), while Utah invokes the Utah Consumer Sales Practices Act and California cites its False Advertising and Unfair Competition laws.

States tighten rules on AI therapy chatbots amid rising mental health use

Seven states have now enacted laws restricting AI-powered therapy chatbots, with five new restrictions taking effect in 2026. Colorado, Maine, Rhode Island, Tennessee, and Vermont joined Illinois and Nevada in prohibiting or severely limiting how artificial intelligence can deliver mental health services. Colorado's law, effective June 3, bars AI therapy chatbots entirely and restricts how licensed professionals can deploy AI tools. Maine treats unauthorized AI therapy as an unfair trade practice. Rhode Island requires that all therapy services be delivered by licensed professionals and prohibits AI from making independent treatment decisions. Tennessee bars AI systems from advertising themselves as qualified mental health professionals. Vermont prohibits AI from independently delivering mental health services. Illinois and Nevada adopted similar restrictions in 2025.

mail Subscribe to Health Care email updates

Primary sources. No fluff. Straight to your inbox.

Also on LawSnap